Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II confirmatory study of TAEST16001 in NY-ESO-1-positive, HLA-A*02:01-positive advanced soft tissue sarcoma
CTR20262246Phase 2Active
- Sponsor
- Xiangxue Precision Medical Technology
- Start
- Jun 2026
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAEST16001 in soft tissue sarcoma (STS), sponsored by Xiangxue Precision Medical Technology. Primary endpoint: Objective response rate. Started Jun 2026; status: active.
02
Drugs
TAEST16001
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20262246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262246.